MASI has a strong position in patient monitoring in hospitals around the country
BEAT wants to dominate mobile monitoring healthcare
Seems like a no-brainer that ECTE will get purchased by one of these two firms.
Looking for $10 buyout.
Quarterly performance has been lower than expected and very disappointing. Most other cloud companies have been growing significantly, while ATTU is showing meager growth.
Now a secondary.
How about generating some revenue and cash flow instead!
Shareholder base has turned over a lot in the past week. Looking for stronger hands and move higher after the sell-off. Looking for Black Rock to add to their position.
Between options and restricted stock, Insiders own a lot of shares already.
What's needed is a better shareholder base and revenue to ramp.
WST, this is backdoor Secondary Offering...Lorem agreed to purchase shares from CYTX and CYTX is now registering those shares for sale to the public. Sorry, that's a Secondary by the transitive property.
P.S. $8 billion - as Chris Berman of ESPN would say, "C'mon Man". This is all smoke and mirrors to get a financing deal done, just like the Seaside deal was a bad deal.
So, you're exactly who I thought you were...a former investor who lost money and is trying to save the world from experiencing the same path you did. Well, forgive me father for I have sinned...I own stock in CLRX, and I am prepared to lose my entire investment, should that happen, as is the case with every stock in the stock market. And, not that I condone Mika and the Board's past mistakes. They clearly saw their semiconductor business become obsolete, and they make bad investments subsequently. But, that does not preclude them from ever getting it right. Just because you made a bad investment in Tegal, doesn't mean you always make bad investments. So, we all appreciate your narrative, for whatever reason you choose to remind us, but many men have failed once or twice before ultimately succeeding.
Depends on who a financing is with. 10-Q states there's enough cash to fund operations for 2014. So, there's clearly a ramp in the next 6 months, otherwise that's false disclosure, and Mika has stated in conference calls that revenue will begin to ramp in 2014. Regardless, I expect an offering at some point in the next 2 quarters. How this is done? Who the investment banker or placement agent is, or what terms CLRX will get, is currently unknown. It will depend on business developments in the next few months, the cash needs, the placement agent, and the future buyers. Having LIFE and DGX as customers and Everyday Health as a partner is meaningful, and given the explosive growth in genetic testing and the exponential number of developments taking place, providing the service / reporting / information that CLRX offers is of clear and growing need. I talk to physicians all the time, every day. Most don't have time to keep up with their medical literature, let alone the dynamic developments going on in genetic medicine. Cliff Notes to strategic decision making, and being able to link to source data, which is what CLRX offers, will only grow exponentially in demand. The market will be there, and clearly LIFE and DGX believe the service offering is compelling. At $12 million of value, that's attractive.
Why don't they sell off non-core assets, like this dental implant thing, and raise funds to expand the 3-D technology?
Don't like to invest in firm with so many disparate businesses that have no synergy.
EQ - what's your point on being on here if you're not short? Are you like trying to do a good deed or something to save people from investing? Seriously, what's your point, motivation, angle, etc.??????????????
A couple of things:
1) There's no way Life Technologies, Quest Diagnostics and Everyday Health don't partner with CLRX unless the product is compelling and provides strong value. That's a fact. Good news that Everyday Health has added the Melanoma Therapy Finder to its MedPage today, joining the Lung Therapy Finder, and continues to expand the relationship.
2) Management is being disciplined on cash burn, with certainly enough cash for the next 2-3 quarters. However, we should expect a secondary offering and welcome it. The reality is that CLRX will need more sales and marketing dollars to really drive home business development and usage of their products by both physicians (oncologists) and patients.
3) Fully diluted shares is 2.9 million, meaning the entire company is worth $12 million, assuming the cash is fully burnt right now.
4) The stock trades poorly...constantly spiking on news only to be shorted by daytraders due to lack of institutional support. The market capitalization and low float prevent institutions from owning the stock. As such, a secondary offering, placed with astute healthcare investors, would be an outstanding development...providing both cash and support for the stock...and potentially increased relationships in the healthcare community.
5) Do not expect much difference in this upcoming quarterly report. This is a development year for a development stage company. 2014 should begin the first signs of increasing revenue and significant operating leverage given the high gross margins (although that will be offset by higher SG&A costs)
Keep thinking of what the private market value would be for CLRX...if this was a Silicon Valley firm with venture capital dollars. It's valuation would be 3x higher right now.
Does every company disclose their deal terms? No, of course not...most don't. C'mon bro, give it up!
Non Exclusive enables CLRX to sign deals with other labs, otherwise, it would be a one-customer shop.
C'mon bro...give it up.
There won't be a revenue ramp until 2014 as that's when the LIFE deal starts kicking in to go along with their increased focus on developing a major testing business. The focus of the call tomorrow should be on how the LIFE deal is progressing, more info on the Quest deal, whether the rollout of the mobile Everyday Health app is ready, what the cash balance / usage / need is going forward, and how to attract better investors...which as you can tell, from all the news pops over the past year, since Tegal bought CollabRx, the result is a gap up in the stock price and massive shorting back down...every single time. So, the stock needs to be in much stronger hands so that the next pop keeps going. This business is worth well more than $12 million. Imagine CLRX was privately held, and they were coming public with Life Technologies and Quest Diagnostics as two of their customers and Everyday Health (similar to WebMD) as a partner. Valuation would be significantly higher. For the stock to be below where it was trading prior to the Quest news speaks to the weak shareholder base and the easy manipulation that can be done with a low float stock. So, this is a key focus going forward. I would welcome dilution to a group of healthcare focused funds, providing CLRX cash and an investor base that would support the stock.
So, you're saying they made up the press release with Quest? So, they don't have both LIFE and Quest as customers? So, you're saying it's all baloney. Give me a break, dude. You know something, if they placed 2 million shares at $4.00 with a healthcare fund, I would be 100% happy about that dilution. Because then that firm would be incentivized to support the stock. There are too many guys like you hanging around here. Too many weak hands. Too many daytraders. Too many shorts. One day soon, the stock will gap open and run, and you'll be calling your friends to borrow money to meet a margin call on your short. Keep shorting.
How is a pump and dump the result of signing a multi-billion dollar diagnostic firm? It's called really good news. The stock got dumped because it's not in strong hands, there are former Tegal shareholders selling at any pop, and a bunch of daytraders taking advantage. The more volume, the better. Shares will move into stronger hands.
All these shorts acting like some boiler room is pumping CLRX. Hello! There was actually BIG news to justify a major move up....and it's going higher...MUCH HIGHER. You don't sign LIFE and DGX and not have a compelling value software / data product. PERIOD. END OF STORY. NO MATTER WHAT YOU SHORTS ARGUE OR SAY. PROOF IS IN THE DEALS.
Short all you want. Keep shorting. Create the biggest short position you can. Please do it. Pretty please. With sugar and cherry on top.
LIFE and DGX do not enter into these agreements unless there is a compelling reason.
The future of diagnostic medicine will have every patient being genetically tested, just like you get blood work done in your annual physicals. Then, patients with cancer, will be further tested to see which patients should get which cancer drugs. Both Roche and Glaxo, for example, are partnering with diagnostic firms to create genetic tests for the protein and enzyme deficiencies or surpluses that are involved in many different cancer types. With the human genome being solved, these genetic tests will go down to the nano level, eventually. And, not only do most physicians not have the time to keep up with the medical literature in medical journals, but the confusion that will be created from the magnitude of tests, therapies and trials, creates an enormous need to have information available giving a clear path of interpretation. That is what CLRX information helps provide...consolidated information from experts to help advise doctors in the field on what to do, what to do next and what's available given the plethora of information.
LIFE and DGX are two of the biggest genetic testing firms in the world and they chose to partner with CLRX, who will make money on each test, as the lab reports of all these tests will include the CLRX information. This data HAS to become standard practice...there is just too much information and not enough time in the day for physicians and other healthcare practitioners to read and understand what's available.
The value of what CLRX is doing...information...is extremely high. It helps decision making, cuts time, personalizes medicine, and saves money.
$15 million market cap....CLRX will be the next 100-bagger.